Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, . . . Saad Z Usmani. (2023). Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Becaris Publishing Limited.
Chicago Style (17th ed.) CitationAmrita Krishnan, et al. Teclistamab Versus Real-world Physician's Choice of Therapy in Triple-class Exposed Relapsed/refractory Multiple Myeloma. Becaris Publishing Limited, 2023.
MLA (9th ed.) CitationAmrita Krishnan, et al. Teclistamab Versus Real-world Physician's Choice of Therapy in Triple-class Exposed Relapsed/refractory Multiple Myeloma. Becaris Publishing Limited, 2023.
Warning: These citations may not always be 100% accurate.